BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Apr 25, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Ganitumab: Phase III started

Takeda began the Japanese portion of a double-blind, international Phase III trial comparing 12 and 20 mg/kg IV ganitumab given on days 1 and 15 of a 28-day cycle plus 1,000 mg/m 2 IV gemcitabine given...

Read the full 156 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >